Rapid and Extensive Expansion in the United States of a New Multidrug-resistant Escherichia coli Clonal Group, Sequence Type 1193

Veronika L. Tchesnokova; Elena Rechkina; Lydia Larson; Kendra Ferrier; Jamie Lee Weaver; David W. Schroeder; Rosemary She; Susan M. Butler-Wu; Maria E. Aguero-Rosenfeld; Danielle Zerr; Ferric C. Fang; James Ralston; Kim Riddell; Delia Scholes; Scott Weissman; Kaveri Parker; Brad Spellberg; James R. Johnson; Evgeni V. Sokurenko

doi:10.1093/cid/ciy525

Rapid and Extensive Expansion in the United States of a New Multidrug-resistant Escherichia coli Clonal Group, Sequence Type 1193

Veronika L. Tchesnokova, Elena Rechkina, Lydia Larson, Kendra Ferrier, Jamie Lee Weaver, David W. Schroeder, Rosemary She, Susan M. Butler-Wu, Maria E. Aguero-Rosenfeld, Danielle Zerr, Ferric C. Fang, James Ralston, Kim Riddell, Delia Scholes, Scott Weissman, Kaveri Parker, Brad Spellberg, James R. Johnson, Evgeni V. Sokurenko

Environmental Health Sciences

Research output: Contribution to journal › Article › peer-review

70 Scopus citations

Abstract

We describe the rapid and ongoing emergence across multiple US cities of a new multidrug-resistant Escherichia coli clone- sequence type (ST) 1193-resistant to fluoroquinolones (100%), trimethoprim-sulfamethoxazole (55%), and tetracycline (53%). ST1193 is associated with younger adults (age <40 years) and currently comprises a quarter of fluoroquinolone-resistant clinical E. coli urine isolates.

Original language	English (US)
Pages (from-to)	334-337
Number of pages	4
Journal	Clinical Infectious Diseases
Volume	68
Issue number	2
DOIs	https://doi.org/10.1093/cid/ciy525
State	Published - Jan 7 2019

Bibliographical note

Funding Information:
Financial support. This work was supported by National Institutes of Health (grant numbers R01AI106007 to E. V. S., and R41AI116114 and R42 AI116114-02 to ID Genomics and E. V. S.); the Office of Research and Development, Medical Research Service, Department of Veterans Affairs (grant number 1 I01 CX000192 01 to J. R. J.); the Partnership for Innovation Award, Group Health Foundation, and Development Fund Award, Group Health Research Institute; and the Gerber Foundation (to E. V. S.).

Funding Information:
Potential conflicts of interest. J. R. J. has received research funding from Achaogen, Allergan, Merck, Syntiron, and Tetraphase; is a consultant for Janssen/Crucell and Syntiron; and has patent applications for tests to detect E. coli strains. V. L. T. and E. V. S. have patent applications to detect E. coli strains. E. V. S. is a major shareholder in ID Genomics. B. S. has received grants and nonfinancial support from Nabriva, Pfizer, Cempra, Bayer, Forge, Shionogi, Alexion, Synthetic Biologics, Paratek, Ovagene, Bioversys, Acurx, Motif, BioAIM, Synthetic Biologics, Mycomed, and ExBaq. F. C. F. has received grants, personal fees, and nonfinancial support from Cepheid and BioFire; grants and nonfinancial support from ELITech; nonfinancial support from Luminex; and personal fees from the Infectious Diseases Society of America. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Publisher Copyright:
© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America.

Keywords

Escherichia coli
Fluoroquinolone resistance
Urinary tract infections

Publisher link

10.1093/cid/ciy525

Find It

Find It at U of M Libraries

Cite this

Tchesnokova, V. L., Rechkina, E., Larson, L., Ferrier, K., Weaver, J. L., Schroeder, D. W., She, R., Butler-Wu, S. M., Aguero-Rosenfeld, M. E., Zerr, D., Fang, F. C., Ralston, J., Riddell, K., Scholes, D., Weissman, S., Parker, K., Spellberg, B., Johnson, J. R., & Sokurenko, E. V. (2019). Rapid and Extensive Expansion in the United States of a New Multidrug-resistant Escherichia coli Clonal Group, Sequence Type 1193. Clinical Infectious Diseases, 68(2), 334-337. https://doi.org/10.1093/cid/ciy525

Tchesnokova, VL, Rechkina, E, Larson, L, Ferrier, K, Weaver, JL, Schroeder, DW, She, R, Butler-Wu, SM, Aguero-Rosenfeld, ME, Zerr, D, Fang, FC, Ralston, J, Riddell, K, Scholes, D, Weissman, S, Parker, K, Spellberg, B, Johnson, JR & Sokurenko, EV 2019, 'Rapid and Extensive Expansion in the United States of a New Multidrug-resistant Escherichia coli Clonal Group, Sequence Type 1193', Clinical Infectious Diseases, vol. 68, no. 2, pp. 334-337. https://doi.org/10.1093/cid/ciy525

@article{6f6669d76d864f8fa86a7d9d2d6f5012,

title = "Rapid and Extensive Expansion in the United States of a New Multidrug-resistant Escherichia coli Clonal Group, Sequence Type 1193",

abstract = "We describe the rapid and ongoing emergence across multiple US cities of a new multidrug-resistant Escherichia coli clone- sequence type (ST) 1193-resistant to fluoroquinolones (100%), trimethoprim-sulfamethoxazole (55%), and tetracycline (53%). ST1193 is associated with younger adults (age <40 years) and currently comprises a quarter of fluoroquinolone-resistant clinical E. coli urine isolates.",

keywords = "Escherichia coli, Fluoroquinolone resistance, Urinary tract infections",

author = "Tchesnokova, {Veronika L.} and Elena Rechkina and Lydia Larson and Kendra Ferrier and Weaver, {Jamie Lee} and Schroeder, {David W.} and Rosemary She and Butler-Wu, {Susan M.} and Aguero-Rosenfeld, {Maria E.} and Danielle Zerr and Fang, {Ferric C.} and James Ralston and Kim Riddell and Delia Scholes and Scott Weissman and Kaveri Parker and Brad Spellberg and Johnson, {James R.} and Sokurenko, {Evgeni V.}",

note = "Funding Information: Financial support. This work was supported by National Institutes of Health (grant numbers R01AI106007 to E. V. S., and R41AI116114 and R42 AI116114-02 to ID Genomics and E. V. S.); the Office of Research and Development, Medical Research Service, Department of Veterans Affairs (grant number 1 I01 CX000192 01 to J. R. J.); the Partnership for Innovation Award, Group Health Foundation, and Development Fund Award, Group Health Research Institute; and the Gerber Foundation (to E. V. S.). Funding Information: Potential conflicts of interest. J. R. J. has received research funding from Achaogen, Allergan, Merck, Syntiron, and Tetraphase; is a consultant for Janssen/Crucell and Syntiron; and has patent applications for tests to detect E. coli strains. V. L. T. and E. V. S. have patent applications to detect E. coli strains. E. V. S. is a major shareholder in ID Genomics. B. S. has received grants and nonfinancial support from Nabriva, Pfizer, Cempra, Bayer, Forge, Shionogi, Alexion, Synthetic Biologics, Paratek, Ovagene, Bioversys, Acurx, Motif, BioAIM, Synthetic Biologics, Mycomed, and ExBaq. F. C. F. has received grants, personal fees, and nonfinancial support from Cepheid and BioFire; grants and nonfinancial support from ELITech; nonfinancial support from Luminex; and personal fees from the Infectious Diseases Society of America. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. Publisher Copyright: {\textcopyright} The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America.",

year = "2019",

month = jan,

day = "7",

doi = "10.1093/cid/ciy525",

language = "English (US)",

volume = "68",

pages = "334--337",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "2",

}

TY - JOUR

T1 - Rapid and Extensive Expansion in the United States of a New Multidrug-resistant Escherichia coli Clonal Group, Sequence Type 1193

AU - Tchesnokova, Veronika L.

AU - Rechkina, Elena

AU - Larson, Lydia

AU - Ferrier, Kendra

AU - Weaver, Jamie Lee

AU - Schroeder, David W.

AU - She, Rosemary

AU - Butler-Wu, Susan M.

AU - Aguero-Rosenfeld, Maria E.

AU - Zerr, Danielle

AU - Fang, Ferric C.

AU - Ralston, James

AU - Riddell, Kim

AU - Scholes, Delia

AU - Weissman, Scott

AU - Parker, Kaveri

AU - Spellberg, Brad

AU - Johnson, James R.

AU - Sokurenko, Evgeni V.

N1 - Funding Information: Financial support. This work was supported by National Institutes of Health (grant numbers R01AI106007 to E. V. S., and R41AI116114 and R42 AI116114-02 to ID Genomics and E. V. S.); the Office of Research and Development, Medical Research Service, Department of Veterans Affairs (grant number 1 I01 CX000192 01 to J. R. J.); the Partnership for Innovation Award, Group Health Foundation, and Development Fund Award, Group Health Research Institute; and the Gerber Foundation (to E. V. S.). Funding Information: Potential conflicts of interest. J. R. J. has received research funding from Achaogen, Allergan, Merck, Syntiron, and Tetraphase; is a consultant for Janssen/Crucell and Syntiron; and has patent applications for tests to detect E. coli strains. V. L. T. and E. V. S. have patent applications to detect E. coli strains. E. V. S. is a major shareholder in ID Genomics. B. S. has received grants and nonfinancial support from Nabriva, Pfizer, Cempra, Bayer, Forge, Shionogi, Alexion, Synthetic Biologics, Paratek, Ovagene, Bioversys, Acurx, Motif, BioAIM, Synthetic Biologics, Mycomed, and ExBaq. F. C. F. has received grants, personal fees, and nonfinancial support from Cepheid and BioFire; grants and nonfinancial support from ELITech; nonfinancial support from Luminex; and personal fees from the Infectious Diseases Society of America. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. Publisher Copyright: © The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America.

PY - 2019/1/7

Y1 - 2019/1/7

N2 - We describe the rapid and ongoing emergence across multiple US cities of a new multidrug-resistant Escherichia coli clone- sequence type (ST) 1193-resistant to fluoroquinolones (100%), trimethoprim-sulfamethoxazole (55%), and tetracycline (53%). ST1193 is associated with younger adults (age <40 years) and currently comprises a quarter of fluoroquinolone-resistant clinical E. coli urine isolates.

AB - We describe the rapid and ongoing emergence across multiple US cities of a new multidrug-resistant Escherichia coli clone- sequence type (ST) 1193-resistant to fluoroquinolones (100%), trimethoprim-sulfamethoxazole (55%), and tetracycline (53%). ST1193 is associated with younger adults (age <40 years) and currently comprises a quarter of fluoroquinolone-resistant clinical E. coli urine isolates.

KW - Escherichia coli

KW - Fluoroquinolone resistance

KW - Urinary tract infections

UR - http://www.scopus.com/inward/record.url?scp=85059024219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059024219&partnerID=8YFLogxK

U2 - 10.1093/cid/ciy525

DO - 10.1093/cid/ciy525

M3 - Article

C2 - 29961843

AN - SCOPUS:85059024219

SN - 1058-4838

VL - 68

SP - 334

EP - 337

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 2

ER -

Rapid and Extensive Expansion in the United States of a New Multidrug-resistant Escherichia coli Clonal Group, Sequence Type 1193

Abstract

Bibliographical note

Keywords

Publisher link

Find It

Other files and links

Fingerprint

Cite this